Functional Profiling of Live Melanoma Samples Using a Novel Automated Platform

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Schayowitz, Adam ^a   Bertenshaw, Greg ^a   Jeffries, Emiko ^a   Schatz, Timothy ^a   Cotton, James ^a   Villanueva, Jessie ^b   Herlyn, Meenhard ^b   Krepler, Clemens ^b   Vultur, Adina ^b   Xu, Wei ^c   Yu, Gordon H ^d   Schuchter, Lynn ^c   Clark, Douglas P ^a  

^a BioMarker Strategies   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOMATION; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG SENSITIVITY; ENZYME ACTIVITY; EX VIVO STUDY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENERAL DEVICE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; MELANOMA CELL; METASTATIC MELANOMA; MOUSE; NONHUMAN; PHARMACODYNAMICS; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOMATION, LABORATORY; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 84871709993     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052760     Document Type: Article

References (34)

1. Sawyers CL, (2008) The cancer biomarker problem. Nature 452: 548-552.
2. Sikorski R, Yao B, (2010) Visualizing the landscape of selection biomarkers in current phase III oncology clinical trials. Sci Transl Med 2: 34ps27.
3. Irish JM, Kotecha N, Nolan GP, (2006) Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 6: 146-155.
4. Avraham R, Yarden Y, (2011) Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12: 104-117.
5. Parkinson DR, Cesano A, (2009) Patient-specific classifications of human malignant disease. Curr Opin Mol Ther 11: 252-259.
6. Fojo T, Parkinson DR, (2010) Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 16: 5972-5980.
7. Poste G, (2011) Bring on the biomarkers. Nature 469: 156-157.
8. Flaherty KT, Hodi FS, Fisher DE, (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12: 349-361.
9. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695.
10. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-972.
11. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
12. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, et al. (2009) MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proceedings of the National Academy of Sciences of the United States of America 106: 20411-20416.
13. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, et al. (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387-390.
14. Shi H, Moriceau G, Kong X, Lee MK, Lee H, et al. (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3: 724.
15. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, et al. (2012) EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2: 227-235.
16. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483: 100-103.
17. Clark DP, (2009) Ex vivo biomarkers: functional tools to guide targeted drug development and therapy. Expert Rev Mol Diagn 9: 787-794.
18. Tsai J, Lee JT, Wang W, Zhang J, Cho H, et al. (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America 105: 3041-3046.
19. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, et al. (2010) RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 70: 5518-5527.
20. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N, (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430.
21. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, et al. (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431-435.
22. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, et al. (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-221.
23. Kaplan FM, Shao Y, Mayberry MM, Aplin AE, (2011) Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 30: 366-371.
24. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599.
25. Herlyn M, Fukunaga-Kalabis M, (2010) What is a good model for melanoma? J Invest Dermatol 130: 911-912.
26. Clark DP, (2009) Seize the opportunity: underutilization of fine-needle aspiration biopsy to inform targeted cancer therapy decisions. Cancer Cytopathol 117: 289-297.
27. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 364: 2507-2516.
28. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714.
29. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, et al. (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367: 107-114.
30. Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, et al. (2012) Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 18: 555-567.
31. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, et al. (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358-365.
32. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, et al. (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71: 2750-2760.
33. Shi H, Kong X, Ribas A, Lo RS, (2011) Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71: 5067-5074.
34. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, et al. (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11: 909-920.